Cadila Pharmaceuticals
Tracked across 4 events · 31 articles · First seen Nov 19, 2025 · Last active Aug 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: The company faces regulatory action including seizure of INR 2.45 crore stock, sales ban, and recall of four drug variants, potentially harming its reputation and market position.
Jul 11, 2026 · 8 articles
Regulatory
The India — Bombay High Court criticized the India — Maharashtra Food and Drug Administration for its drastic action against Cadila Pharmaceuticals, which had banned the sale and distribution of certain medicines and seized stock…
Impact: Cadila Pharmaceuticals challenged the FDA's ban and seizure of its medicines. The court's intervention led to the FDA revoking its orders, providing temporary relief, though the company still faces potential regulatory action after a hearing.
Aug 11, 2026 · 9 articles
Tech
Impact: Cadila Pharmaceuticals co-developed the Immuvac vaccine, which was tested in the PreVenTB trial for its safety and efficacy against tuberculosis.
Apr 10, 2026 · 6 articles
Business
Impact: Cadila Pharmaceuticals is a marquee customer of Sudeep Pharma.
Nov 19, 2025 · 8 articles
ERGEN INTELLIGENCE
Track Cadila Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard